APA (7th ed.) Citation

S, M., N, G., QA, K., NY, Z., E, C., C, B., . . . S, A. K. (2020). Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: Study protocol for the first-in-human CAPRISA 012B phase I clinical trial. BMJ open, 10(11), e042247. https://doi.org/10.1136/bmjopen-2020-042247

Chicago Style (17th ed.) Citation

S, Mahomed, et al. "Assessing the Safety and Pharmacokinetics of the Anti-HIV Monoclonal Antibody CAP256V2LS Alone and in Combination with VRC07-523LS and PGT121 in South African Women: Study Protocol for the First-in-human CAPRISA 012B Phase I Clinical Trial." BMJ Open 10, no. 11 (2020): e042247. https://doi.org/10.1136/bmjopen-2020-042247.

MLA (9th ed.) Citation

S, Mahomed, et al. "Assessing the Safety and Pharmacokinetics of the Anti-HIV Monoclonal Antibody CAP256V2LS Alone and in Combination with VRC07-523LS and PGT121 in South African Women: Study Protocol for the First-in-human CAPRISA 012B Phase I Clinical Trial." BMJ Open, vol. 10, no. 11, 2020, p. e042247, https://doi.org/10.1136/bmjopen-2020-042247.